Biospecimen Reporting for Improved Study Quality (BRISQ)

被引:104
作者
Moore, Helen M. [2 ]
Kelly, Andrea B. [3 ]
Jewell, Scott D. [4 ]
McShane, Lisa M. [5 ]
Clark, Douglas P. [1 ]
Greenspan, Renata [6 ]
Hayes, Daniel F. [7 ]
Hainaut, Pierre [8 ]
Kim, Paula [9 ]
Mansfield, Elizabeth A. [10 ]
Potapova, Olga [11 ]
Riegman, Peter [12 ]
Rubinstein, Yaffa [13 ]
Seijo, Edward [14 ]
Somiari, Stella [15 ]
Watson, Peter [16 ]
Weier, Heinz-Ulrich [17 ]
Zhu, Claire [18 ]
Vaught, Jim [2 ]
机构
[1] Johns Hopkins Univ Hosp, Dept Pathol, Baltimore, MD 21287 USA
[2] Natl Canc Inst, Off Biorepositories & Biospecimen Res, Bethesda, MD USA
[3] Rose Li & Associates Inc, Bethesda, MD USA
[4] Van Andel Res Inst, Program Biospecimen Sci, Grand Rapids, MI USA
[5] NCI, Div Canc Treatment & Diag, Biometr Res Branch, Bethesda, MD 20892 USA
[6] Henry M Jackson Fdn Adv Mil Med, US Mil Canc Inst, Rockville, MD USA
[7] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA
[8] World Hlth Org, IARC, Lyon, France
[9] Paula Kim Inc, TRAC, Solana Beach, CA USA
[10] US Dept HHS, Ctr Devices & Radiol Hlth, US FDA, Silver Spring, MD USA
[11] Cureline Inc, San Francisco, CA USA
[12] Erasmus MC Tissue Bank, Dept Pathol, Rotterdam, Netherlands
[13] NIH, Off Rare Dis Res, Bethesda, MD 20892 USA
[14] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[15] Windber Res Inst, Windber, PA USA
[16] British Columbia Canc Agcy, Vancouver Isl Ctr, Victoria, BC, Canada
[17] US DOE, Div Life Sci, Lawrence Berkeley Natl Lab, Berkeley, CA USA
[18] NCI, Canc Prevent Div, Bethesda, MD 20892 USA
基金
美国国家卫生研究院;
关键词
BRISQ; best practices; biobank; biospecimen; human; quality; research; guidelines; APPROACHING CLINICAL PROTEOMICS; FUTURE FIELDS; CURRENT STATE; TISSUE;
D O I
10.1002/cncy.20147
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Human biospecimens are subjected to collection, processing, and storage that can significantly alter their molecular composition and consistency. These biospecimen preanalytical factors, in turn, influence experimental outcomes and the ability to reproduce scientific results. Currently, the extent and type of information specific to the biospecimen preanalytical conditions reported in scientific publications and regulatory submissions varies widely. To improve the quality of research that uses human tissues, it is crucial that information on the handling of biospecimens be reported in a thorough, accurate, and standardized manner. The Biospecimen Reporting for Improved Study Quality (BRISQ) recommendations outlined herein are intended to apply to any study in which human biospecimens are used. The purpose of reporting these details is to supply others, from researchers to regulators, with more consistent and standardized information to better evaluate, interpret, compare, and reproduce the experimental results. The BRISQ guidelines are proposed as an important and timely resource tool to strengthen communication and publications on biospecimen-related research and to help reassure patient contributors and the advocacy community that their contributions are valued and respected. Cancer (Cancer Cytopathol) 2011;119:92-101. Published 2011 by the American Cancer Society.*
引用
收藏
页码:92 / 101
页数:10
相关论文
共 11 条
  • [1] Approaching Clinical Proteomics: Current State and Future Fields of Application in Cellular Proteomics
    Apweiler, Rolf
    Aslanidis, Charalampos
    Deufel, Thomas
    Gerstner, Andreas
    Hansen, Jens
    Hochstrasser, Dennis
    Kellner, Roland
    Kubicek, Markus
    Lottspeich, Friedrich
    Maser, Edmund
    Mewes, Hans-Werner
    Meyer, Helmut E.
    Muellner, Stefan
    Mutter, Wolfgang
    Neumaier, Michael
    Nollau, Peter
    Nothwang, Hans G.
    Ponten, Fredrik
    Radbruch, Andreas
    Reinert, Knut
    Rothe, Gregor
    Stockinger, Hannes
    Tarnok, Attila
    Taussig, Mike J.
    Thiel, Andreas
    Thiery, Joachim
    Ueffing, Marius
    Valet, Guenther
    Vandekerckhove, Joel
    Wagener, Christoph
    Wagner, Oswald
    Schmitz, Gerd
    [J]. CYTOMETRY PART A, 2009, 75A (10) : 816 - 832
  • [2] Approaching clinical proteomics: current state and future fields of application in fluid proteomics
    Apweiler, Rolf
    Aslanidis, Charalampos
    Deufel, Thomas
    Gerstner, Andreas
    Hansen, Jens
    Hochstrasser, Dennis
    Kellner, Roland
    Kubicek, Markus
    Lottspeich, Friedrich
    Maser, Edmund
    Mewes, Hans-Werner
    Meyer, Helmut E.
    Muellner, Stefan
    Mutter, Wolfgang
    Neumaier, Michael
    Nollau, Peter
    Nothwang, Hans G.
    Ponten, Fredrik
    Radbruch, Andreas
    Reinert, Knut
    Rothe, Gregor
    Stockinger, Hannes
    Tarnok, Attila
    Taussig, Mike J.
    Thiel, Andreas
    Thiery, Joachim
    Ueffing, Marius
    Valet, Guenther
    Vandekerckhove, Joel
    Verhuven, Wiltrud
    Wagener, Christoph
    Wagner, Oswald
    Schmitz, Gerd
    [J]. CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2009, 47 (06) : 724 - 744
  • [3] HER-2/neu detection in fine-needle aspirates of breast cancer - Fluorescence in situ hybridization and immunocytochemical analysis
    Beatty, BG
    Bryant, R
    Wang, WC
    Ashikaga, T
    Gibson, PC
    Leiman, G
    Weaver, DL
    [J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2004, 122 (02) : 246 - 255
  • [4] Standard Preanalytical Coding for Biospecimens: Defining the Sample PREanalytical Code
    Betsou, Fotini
    Lehmann, Sylvain
    Ashton, Garry
    Barnes, Michael
    Benson, Erica E.
    Coppola, Domenico
    DeSouza, Yvonne
    Eliason, James
    Glazer, Barbara
    Guadagni, Fiorella
    Harding, Keith
    Horsfall, David J.
    Kleeberger, Cynthia
    Nanni, Umberto
    Prasad, Anil
    Shea, Kathi
    Skubitz, Amy
    Somiari, Stella
    Gunter, Elaine
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2010, 19 (04) : 1004 - 1011
  • [5] Tissue is alive: New technologies are needed to address the problems of protein biomarker pre-analytical variability
    Espina, Virginia
    Mueller, Claudius
    Edmiston, Kirsten
    Sciro, Manuela
    Petricoin, Emanuel F.
    Liotta, Lance A.
    [J]. PROTEOMICS CLINICAL APPLICATIONS, 2009, 3 (08) : 874 - 882
  • [6] Reporting recommendations for tumor marker prognostic studies (REMARK)
    McShane, LM
    Altman, DG
    Sauerbrei, W
    Taube, SE
    Gion, M
    Clark, GM
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (16): : 1180 - 1184
  • [7] Moore Helen M, 2009, Cancer Res, V69, P6770, DOI 10.1158/0008-5472.CAN-09-1795
  • [8] Sources of Bias in Specimens for Research About Molecular Markers for Cancer
    Ransohoff, David F.
    Gourlay, Margaret L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (04) : 698 - 704
  • [9] Informed consent in biobank research: A deliberative approach to the debate
    Secko, David M.
    Preto, Nina
    Niemeyer, Simon
    Burgess, Michael M.
    [J]. SOCIAL SCIENCE & MEDICINE, 2009, 68 (04) : 781 - 789
  • [10] Effect of fixatives and tissue processing on the content and integrity of nucleic acids
    Srinivasan, M
    Sedmak, D
    Jewell, S
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 2002, 161 (06) : 1961 - 1971